SavedAdd your journal

Journals / Erciyes Medical Journal / 2016 / Cilt: 38 - Sayı: 4

Nontuberculous Mycobacterial Infection in a Patient Diagnosed with Ankylosing Spondylitis

Nigar DİRİCAN
Merve PINAR
Seven ERTURK
Şule ATALAY
MÜNİRE ÇAKIR
Pages
162–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article aims to present an atypical mycobacterial infection in a patient in whom anti-tumor necrosis factor alpha therapy was being planned and who was followed up with diagnoses of ankylosing spondylitis and COPD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nontuberculous mycobacteria are common microorganisms in nature and are particularly found in soil and water.
📊
Key Findings & Data:They cause pulmonary infections, lymphadenitis, disseminated infections, localized skin and soft tissue infections, tendon-bone-articular infections, and catheter infections.
💡
Conclusion & Impact:This article aims to present an atypical mycobacterial infection in a patient in whom anti-tumor necrosis factor alpha therapy was being planned and who was followed up with diagnoses of ankylosing spondylitis and COPD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nontuberculous mycobacteria are common microorganisms in nature and are particularly found in soil and water. They cause pulmonary infections, lymphadenitis, disseminated infections, localized skin and soft tissue infections, tendon-bone-articular infections, and catheter infections. Mycobacterium xenopi is categorized as a slow-growing mycobacterium. Pulmonary infections caused by M. xenopi have been found to be associated with chronic obstructive pulmonary disease (COPD), underlying diseases such as bronchiectasis, and immunosuppression. This article aims to present an atypical mycobacterial infection in a patient in whom anti-tumor necrosis factor alpha therapy was being planned and who was followed up with diagnoses of ankylosing spondylitis and COPD.

🔖

Cite This Article

DİRİCAN, N., PINAR, M., ERTURK, S., ATALAY, Ş., ÇAKIR, M. (2016). Nontuberculous Mycobacterial Infection in a Patient Diagnosed with Ankylosing Spondylitis. Erciyes Medical Journal, Cilt: 38 - Sayı: 4, 162–164. https://ajindex.com/articles/204247

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Tortoli E. Microbiological features and clinical relevance of new spe- cies of the genus Mycobacterium. Clinical Microbiology Reviews 2014; 27(4): 727-52. [CrossRef] Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontu- berculous mycobacterial disease prevalence and risk factors: a chang- ing epidemiology. Clin Infect Dis 2009; 49(12): 124-9. [CrossRef] Mirsaeidi M, Machado RF, Garcia JGN, Schraufnagel DE. Nontuber- culous mycobacterial disease mortality in the United States, 1999- 2010: a population-based comparative study. PLoS ONE 2014; 9: e91879. [CrossRef] Mirsaeidi M, Farshidpour M, Ebrahimi G, Aliberti S, Falkinham III JO. Management of nontuberculous mycobacterial infection in the elderly. European Journal of Internal Medicine 2014; 25(4): 356-63. [CrossRef] Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria iso- lated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42(6): 1604-13. [CrossRef] Marras TK, Wagnetz U, Jamieson FB, Patsios DA. Chest computed to- mography predicts microbiological burden and symptoms in pulmonary Mycobacterium xenopi. Respirology 2013; 18(1): 92-101. [CrossRef] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley, C, Gordin F. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175(4): 367-416. [CrossRef] Marusic A, Katalinic-Jankovic V, Popovic-Grle S, Jankovic M, Mazuranic I, Puljic I et al. Mycobacterium xenopi pulmonary disease Epidemiology and clinical features in non-immunocompromised pa- tients. J Infect 2009; 58(2): 108-12. [CrossRef] Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Non- tuberculous mycobacteria infections and antitumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15(10): 1556-61. [CrossRef] Andre´jak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Du- haut P et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181(5): 514-21.[CrossRef]